Drug Therapy and Interactions in Pediatric Oncology, 1st ed. 2017
A Pocket Guide

There are few publications about drug interactions in chemotherapy and even less about pediatric oncology treatment. For this reason, the present book is intended to offer guidelines about drug interactions for physicians, pharmacists and the other healthcare professionals involved in the chemotherapy of pediatric patients. In this book the reader will have access to a primary introduction for the major diseases in pediatric oncology, followed by the major therapeutic protocols. Following that, the most important drug interactions in pediatric oncology treatment are presented and discussed in detail. Finally, important topics such as Drug-Food Interactions are addressed. 

Drug Therapy and Interactions in Pediatric Oncology focuses in great detail on the drug interactions in Pediatric Oncohematology and will be an indispensable resource in daily practice for a wide range of health providers.

1. Introduction.- 
2. The Main Diseases In Pediatric Oncohematology
2.1. Hodgkin Lymphoma
2.2. Chronic Myeloid Leukemia (CML)
2.3. Acute Myeloid Leukemia (AML)
2.4. Acute Lymphoblastic Leukemia (ALL)
2.5. Osteosarcoma
2.6. Central Nervous System Tumors.- 
3. The Main Protocols In Pediatric Oncohematology
3.1. Hodgkin Lymphoma
3.2. Chronic Myeloid Leukemia (CML)
3.3. Hematologic Control with Hydroxyurea
3.4. Acute Myeloid Leukemia (AML)
3.5. Acute Myeloid Leukemia - Berlin-Frankfurt-Münster Treatment (BFM2004) – adapted from HEMORIO
3.6. Acute Myeloid Leukemia - Berlin-Frankfurt-Münster Treatment (BFM95)
3.7. Brain Tumors
3.8. High Dose Protocol – HD-CAV (Neuroblastoma)
3.9. COPE/Baby Brain I
3.10. 8 in 1 Chemotherapy
3.11. CAV-P/VP (Neuroblastoma)
3.12. Wilms Tumor
3.13. AVD
3.14. AV (Wilms Tumor Stage IV and Favorable Histology)
3.15. Advanced Burkkit Lymphoma and ALL L3
3.16. Burkkit Lymphoma Protocol LMB89
3.17. Retinoblastoma
3.18. Non-Hodgkin Lymphoma
3.19. CODOX-M
3.20. Osteosarcoma
3.21. HD MTX
3.22. ICE
3.23. Hepatoblastoma.- 
4. Background On Drug Interactions
4.1. General Concepts
4.2. Pharmacokinetic Interactions
4.3. Pharmacodynamic Interactions
4.4. Beneficial Drug Interactions of Clinical Protocols
4.5. Methotrexate with Leocovorin
4.6. Doxorubicin with Dexrazoxane
4.7. Mesna with Ifosfamide or with Cyclophosphamide
4.8. Methotrexate with Sodium Bicarbonate
4.9. Drug-drug Interactions
4.10. Pharmacokinetic Drug Interactions with CYP450
4.11. Pharmacokinetic Drug Interactions with CYP450: Anticonvulsant
4.12. Pharmacokinetic Drug Interactions Involving Binding Proteins and Plasmatic Proteins Affinity
4.13. α1- Acid Glycoprotein
4.14. Albumin
4.15. Pharmacokinetic Drug Interactions Involving Transport Proteins
4.16. P Glycoprotein
4.17. ATP Binding Cassettes
4.18. Drug Interactions Involving Prodrugs
4.19. Drug Interactions between Methotrexate and Nonsteroidal Anti-inflammatory Drugs
4.20. 6-Mercaptopurin and Allopurinol
4.21. Antineoplasics and Antiemetics
4.22. Aprepitant
4.23. Dexamethasone with Antineoplasics
4.24. Antacids with Antineoplasics
4.25. Antimicrobial Drugs with Antineoplasics
4.26. Macrolides Antimicrobial
4.27. Aminoglicosydes Antimicrobial
4.28. Tuberculosis Antimicrobial Drugs
4.29. Ceftriaxhone and Platinum Composers
4.30. Penicilamic Antibiotical Drug and Antineoplasics
4.31. Sulfamethoxazole withTrimethoprim and Methotrexate
4.32. Antineoplasics and Antifungics
4.33. Amphotericin B
4.34. Azolic Antifungics
4.35. Anticonvulsant and Antineoplasics.- 
5. Food - Drug Interactions.- 
6. Body Surface.- 
7. Carboplatin Dosage Calculation.- 
8. Creatinine Clearance Estimate

Carolina Witchmichen Penteado Schmidt: Oncology Pharmacist with extensive experience with Pediatric Oncohematology and Chemotherapy in Children. Oncological Hospital Pharmacy Specialist; Planning and Business Management Specialist. Extensive experience in hospitals and clinics, with Pharmacy, Drug Interactions, Pediatrics, Oncology, Hematology, Neonatology, Intensive Health Care and Infectology. Academic experience in the following fields: Pharmacy, Pediatrics, Oncology and Hematology.

Fabiana Gatti de Menezes: Graduated in Pharmacy and Biochemistry, University of São Paulo, Brazil. Master in Pharmacology, Faculty of Medical Sciences, State University of Campinas, Brazil; PhD in Pharmacology, Institute of Biomedical Sciences of University of São Paulo, Brazil; Specialization in Clinical Pharmacy at Hospital Israelita Albert Einstein, Brazil. Professor and researcher in the following areas: Clinical Pharmacy, Pharmacoepidemiology and Pharmaceutical Care. Professor of Pharmacotherapy, Clinical Research Pharmacy and Clinical Pharmacy at postgraduate courses: Hospital Pharmacy (Oswaldo Cruz College, Brazil); Hospital and Clinical Pharmacology (Gama Filho University, Brazil); Oncological Hospital Pharmacy (AC Camargo Cancer Center, Brazil). Experience in Clinical Pharmacy: Pharmaceutical Care, Pharmacoepidemiology, Pharmacovigilance, Pharmacoeconomics, Hospital Pharmacy, Drug Interactions, and Industry.